Tapentadol
CA: CDSA Schedule I Section 22 Tapentadol
UK: MDA Part I Class A Section 1(a) Tapentadol
US: CSA Schedule II Section c Subsection 28 Tapentadol
⇒
PubChem: 9838022; ChemSpider: 8013742; Bluelight: Tapentadol; Drugs Forum: Tapentadol; Erowid: Tapentadol; Wikipedia: Tapentadol
TCP
CA: CDSA Schedule III Section 14 1-[1-(2-Thienyl)cyclohexyl]piperidine
UK: MDA Part I Class A Section 1(a) Tenocyclidine
UN: Psychotropics Schedule I Tenocyclidine (TCP)
US: CSA Schedule I Section d Subsection 34 Thiophene analog of Phencyclidine
⇒
PubChem: 62751; ChemSpider: 56495; Bluelight: PCP analogs; Drugs Forum: Tenocyclidine; Wikipedia: Tenocyclidine
TCPy
UK: MDA Part II Class B Section 1(d) TCPy
US: CSA Schedule I Section d Subsection 35 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine
Tenamfetamine
CA: CDSA Schedule I Section 19 Subsection 4 3,4-Methylenedioxyamphetamine (MDA)
CA: [revoked] CDSA Schedule III Section 1 Subsection 5 3,4-Methylenedioxyamphetamine (MDA)
UK: MDA Part I Class A Section 1(c) 3,4-Methylenedioxyamphetamine
UN: Psychotropics Schedule I Tenamfetamine (MDA)
US: CSA Schedule I Section d Subsection 10 3,4-Methylenedioxyamphetamine
Tenocyclidine
CA: CDSA Schedule III Section 14 1-[1-(2-Thienyl)cyclohexyl]piperidine
UK: MDA Part I Class A Section 1(a) Tenocyclidine
UN: Psychotropics Schedule I Tenocyclidine (TCP)
US: CSA Schedule I Section d Subsection 34 Thiophene analog of Phencyclidine
⇒
PubChem: 62751; ChemSpider: 56495; Bluelight: PCP analogs; Drugs Forum: Tenocyclidine; Wikipedia: Tenocyclidine
Testolactone
US: CSA Schedule III Section f Subsection 1 Item 61 Testolactone
Testosterone
CA: CDSA Schedule IV Section 23 Subsection 40 Testosterone
UK: MDA Part III Class C Section 1(b) Testosterone
US: CSA Schedule III Section f Subsection 1 Item 62 Testosterone
1-Testosterone
US: CSA Schedule III Section f Subsection 1 Item 18 Δ1-Dihydrotestosterone
Tetrahydrocannabinol
CA: CDSA Schedule II Section 1 Subsection 7 Tetrahydrocannabinol
UK: MDA Part II Class B Section 1(a) Tetrahydrocannabinol
US: CSA Schedule I Section d Subsection 31 Δ1 cis or trans Tetrahydrocannabinol
⇒
PubChem: 16078; ChemSpider: 4479482; Bluelight: Tetrahydrocannabinol; Erowid: Cannabis; Wikipedia: TetrahydrocannabinolTetrahydrocannabinol
UN: Psychotropics Schedule I Tetrahydrocannabinol
Δ1 cis or trans Tetrahydrocannabinol
CA: CDSA Schedule II Section 1 Subsection 7 Tetrahydrocannabinol
UK: MDA Part II Class B Section 1(a) Tetrahydrocannabinol
US: CSA Schedule I Section d Subsection 31 Δ1 cis or trans Tetrahydrocannabinol
⇒
PubChem: 16078; ChemSpider: 4479482; Bluelight: Tetrahydrocannabinol; Erowid: Cannabis; Wikipedia: Tetrahydrocannabinol
Δ3,4 cis or trans Tetrahydrocannabinol
UN: Psychotropics Schedule I 7,8,9,10-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol
US: CSA Schedule I Section d Subsection 31 Δ3,4 cis or trans Tetrahydrocannabinol
Δ6 cis or trans Tetrahydrocannabinol
UN: Psychotropics Schedule I (6aR,10aR)-6a,7,10,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol
US: CSA Schedule I Section d Subsection 31 Δ6 cis or trans Tetrahydrocannabinol
Tetrahydrocannabinols
US: CSA Schedule I Section d Subsection 31 Tetrahydrocannabinols
Tetrahydrogestrinone
UK: MDA Part III Class C Section 1(b) Tetrahydrogestrinone
US: CSA Schedule III Section f Subsection 1 Item 63 Tetrahydrogestrinone
⇒
PubChem: 25320811 6857686; ChemSpider: 5257020; Bluelight: Tetrahydrogestrinone; Erowid: Steroids; Wikipedia: Tetrahydrogestrinone![3D rendering of 6a,7,8,9-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol](data:image/png;base64,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 "Click for a 3D rendering of 6a,7,8,9-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol")
6a,7,8,9-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol
UN: Psychotropics Schedule I 6a,7,8,9-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol
(6aR,10aR)-6a,7,10,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol
UN: Psychotropics Schedule I (6aR,10aR)-6a,7,10,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol
US: CSA Schedule I Section d Subsection 31 Δ6 cis or trans Tetrahydrocannabinol
![3D rendering of (6aR,9R,10aR)-6a,9,10,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol](data:image/png;base64,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 "Click for a 3D rendering of (6aR,9R,10aR)-6a,9,10,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol")
(6aR,9R,10aR)-6a,9,10,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol
UN: Psychotropics Schedule I (6aR,9R,10aR)-6a,9,10,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol
7,8,9,10-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol
UN: Psychotropics Schedule I 7,8,9,10-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol
US: CSA Schedule I Section d Subsection 31 Δ3,4 cis or trans Tetrahydrocannabinol
![3D rendering of (9R,10aR)-8,9,10,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol](data:image/png;base64,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 "Click for a 3D rendering of (9R,10aR)-8,9,10,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol")
(9R,10aR)-8,9,10,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol
UN: Psychotropics Schedule I (9R,10aR)-8,9,10,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol
β,3,4,5-Tetramethoxyphenethylamine
UK: MDA Part I Class A Section 1(ba) β,3,4,5-Tetramethoxyphenethylamine
3-(2,2,3,3-Tetramethylcyclopropylcarbonyl)indole
UK: MDA Part II Class B Section 1(c) 3-(2,2,3,3-Tetramethylcyclopropylcarbonyl)indole
Tetrazepam
CA: CDSA Schedule IV Section 18 Subsection 31 Tetrazepam
UK: MDA Part III Class C Section 1(a) Tetrazepam
UN: Psychotropics Schedule IV Tetrazepam
US: CSA Schedule IV Section c Subsection 51 Tetrazepam
⇒
PubChem: 25215; ChemSpider: 23551; Bluelight: Tetrazepam; Drugs Forum: Tetrazepam; Wikipedia: Tetrazepam
TFMPP
CA: CDSA Schedule III Section 34 Trifluoromethylphenylpiperazine
⇒
PubChem: 4296; ChemSpider: 4145; Bluelight: BZP + TFMPP; Drugs Forum: TFMPP; Erowid: TFMPP; Wikipedia: Trifluoromethylphenylpiperazine
Thialbarbital
CA: CDSA Schedule IV Section 2 Subsection 1 Thialbarbital
Thiambutenes
CA: CDSA Schedule I Section 8 Thiambutenes
1-[1-(2-Thienyl)cyclohexyl]piperidine
CA: CDSA Schedule III Section 14 1-[1-(2-Thienyl)cyclohexyl]piperidine
UK: MDA Part I Class A Section 1(a) Tenocyclidine
UN: Psychotropics Schedule I Tenocyclidine (TCP)
US: CSA Schedule I Section d Subsection 34 Thiophene analog of Phencyclidine
⇒
PubChem: 62751; ChemSpider: 56495; Bluelight: PCP analogs; Drugs Forum: Tenocyclidine; Wikipedia: Tenocyclidine
1-[1-(2-Thienyl)cyclohexyl]pyrrolidine
UK: MDA Part II Class B Section 1(d) TCPy
US: CSA Schedule I Section d Subsection 35 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine
Thiobarbiturates
CA: CDSA Schedule IV Section 2 Thiobarbiturates
Thiobarbituric acid
CA: CDSA Schedule IV Section 2 Subsection 3 Thiobarbituric acid
Thiofentanyl
CA: CDSA Schedule I Section 16 Subsection 13 Thiofentanyl
UK: MDA Part I Class A Section 1(d) Thiofentanyl
UN: Narcotics Part 1 Section 1 Thiofentanyl and Section 3 Thiofentanyl
US: CSA Schedule I Section b Subsection 53 Thiofentanyl
Thiomesterone
CA: CDSA Schedule IV Section 23 Subsection 42 Tiomesterone
UK: MDA Part III Class C Section 1(b) Thiomesterone
Thiopental
CA: CDSA Schedule IV Section 2 Subsection 4 Thiopental
Thiophene analog of Phencyclidine
CA: CDSA Schedule III Section 14 1-[1-(2-Thienyl)cyclohexyl]piperidine
UK: MDA Part I Class A Section 1(a) Tenocyclidine
UN: Psychotropics Schedule I Tenocyclidine (TCP)
US: CSA Schedule I Section d Subsection 34 Thiophene analog of Phencyclidine
⇒
PubChem: 62751; ChemSpider: 56495; Bluelight: PCP analogs; Drugs Forum: Tenocyclidine; Wikipedia: Tenocyclidine
THJ-2201
US: CSA Schedule I Section h Subsection 23 [1-(5-Fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone
Tiletamine
US: CSA Schedule III Section c Subsection 15 Tiletamine
⇒
PubChem: 26533; ChemSpider: 24714; Bluelight: Tiletamine; Drugs Forum: Tiletamine; Erowid: Tiletamine; Wikipedia: Tiletamine
Tincture of opium
US: CSA Schedule II Section b Subsection 1 Item xviii Tincture of opium
Tiomesterone
CA: CDSA Schedule IV Section 23 Subsection 42 Tiomesterone
UK: MDA Part III Class C Section 1(b) Thiomesterone
TMA
CA: CDSA Schedule I Section 19 Subsection 21 3,4,5-Trimethoxyamphetamine
CA: [revoked] CDSA Schedule III Section 1 Subsection 22 3,4,5-Trimethoxyamphetamine
UK: MDA Part I Class A Section 1(c) 3,4,5-Trimethoxyamphetamine
UN: Psychotropics Schedule I TMA
US: CSA Schedule I Section d Subsection 14 3,4,5-Trimethoxyamphetamine
⇒
PubChem: 31016; ChemSpider: 28775; Bluelight: TMA and isomers; Drugs Forum: TMA 2; Erowid: TMA-2 (and other TMAs); PiHKAL • info: TMA; Wikipedia: Trimethoxyamphetamine
TPCP
CA: CDSA Schedule III Section 14 1-[1-(2-Thienyl)cyclohexyl]piperidine
UK: MDA Part I Class A Section 1(a) Tenocyclidine
UN: Psychotropics Schedule I Tenocyclidine (TCP)
US: CSA Schedule I Section d Subsection 34 Thiophene analog of Phencyclidine
⇒
PubChem: 62751; ChemSpider: 56495; Bluelight: PCP analogs; Drugs Forum: Tenocyclidine; Wikipedia: Tenocyclidine
Tranzene®
CA: CDSA Schedule IV Section 18 Subsection 7 Clorazepate
Trenbolone
CA: CDSA Schedule IV Section 23 Subsection 43 Trenbolone
UK: MDA Part III Class C Section 1(b) Trenbolone
US: CSA Schedule III Section f Subsection 1 Item 64 Trenbolone
Trifluoromethylphenylpiperazine‡
CA: CDSA Schedule III Section 34 Trifluoromethylphenylpiperazine
⇒
PubChem: 4296; ChemSpider: 4145; Bluelight: BZP + TFMPP; Drugs Forum: TFMPP; Erowid: TFMPP; Wikipedia: Trifluoromethylphenylpiperazine
1-(3-Trifluoromethylphenyl)piperazine
CA: CDSA Schedule III Section 34 Trifluoromethylphenylpiperazine
⇒
PubChem: 4296; ChemSpider: 4145; Bluelight: BZP + TFMPP; Drugs Forum: TFMPP; Erowid: TFMPP; Wikipedia: Trifluoromethylphenylpiperazine
Trilostane
UK: [not controlled] MDA Part III Class C Section 1(c) Trilostane
Trimeperidine
CA: CDSA Schedule I Section 3 Subsection 21 Trimeperidine
UK: MDA Part I Class A Section 1(a) Trimeperidine
UN: Narcotics Part 1 Section 1 Trimeperidine
US: CSA Schedule I Section b Subsection 55 Trimeperidine
Trimethoxyamphetamine‡
CA: CDSA Schedule I Section 19 Subsection 7 2,4,5-Trimethoxyamphetamine
CA: [revoked] CDSA Schedule III Section 1 Subsection 8 2,4,5-Trimethoxyamphetamine
EU: Substances Substances TMA-2
UK: MDA Part I Class A Section 1(c) 2,4,5-Trimethoxyamphetamine
2,4,5-Trimethoxyamphetamine
CA: CDSA Schedule I Section 19 Subsection 7 2,4,5-Trimethoxyamphetamine
CA: [revoked] CDSA Schedule III Section 1 Subsection 8 2,4,5-Trimethoxyamphetamine
EU: Substances Substances TMA-2
UK: MDA Part I Class A Section 1(c) 2,4,5-Trimethoxyamphetamine
3,4,5-Trimethoxyamphetamine
CA: CDSA Schedule I Section 19 Subsection 21 3,4,5-Trimethoxyamphetamine
CA: [revoked] CDSA Schedule III Section 1 Subsection 22 3,4,5-Trimethoxyamphetamine
UK: MDA Part I Class A Section 1(c) 3,4,5-Trimethoxyamphetamine
UN: Psychotropics Schedule I TMA
US: CSA Schedule I Section d Subsection 14 3,4,5-Trimethoxyamphetamine
⇒
PubChem: 31016; ChemSpider: 28775; Bluelight: TMA and isomers; Drugs Forum: TMA 2; Erowid: TMA-2 (and other TMAs); PiHKAL • info: TMA; Wikipedia: Trimethoxyamphetamine
β,2,5-Trimethoxy-4-methylphenethylamine
UK: MDA Part I Class A Section 1(ba) β,2,5-Trimethoxy-4-methylphenethylamine
Tryptamine
UK: MDA Part I Class A Section 1(b) Tryptamine
11 March 2016 · 
· Isomer Design
· Isomer Design